Loading
A phase 3 trial of Nuvastatic 300 in triple-negative breast cancer, run by Natureceuticals Sdn Bhd, now recruiting.
Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer is a phase 3 interventional study registered as NCT07669467 by Natureceuticals Sdn Bhd, with 250 participants planned, started 2025-10-01 and due to reach its primary completion in 2026-10-30. Interventions recorded: Nuvastatic 300 and Placebo.
Shares NatureCeuticals and the tag pipeline.
Shares NatureCeuticals and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.